Latest News



Click here to watch Dr. Courtney Casserly discuss the case and the responses to the survey.

Janet, 58, currently works full-time running an animal grooming business. She is married with two adult children.  She was diagnosed in 1997 with RRMS after presenting with two mild relapses. MRI at that time revealed a low T2 burden of disease. She was initially hesitant about starting treatment. In 2003, she initiated therapy with interferon-beta-1b after experiencing a moderately-severe relapse with some residual disability. EDSS was 1.5. Read More

The end of MS phenotypes?


The International Advisory Committee on Clinical Trials in Multiple Sclerosis is recommending that the clinical course descriptions of MS – relapsing-remitting (RRMS), secondary-progressive (SPMS) and primary-progressive (PPMS) – be discarded in favour of a more biology-based approach (Kuhlmann et al. Lancet Neurol 2022; epublished November 18, 2022). Read More


MS Awards 2022 – Oddities and Observations


MS Prodromedary Prize
A study in Saudi Arabia found that the most important risk factor for the development of MS was consumption of camel milk (odds ratio 2.50) (Alkhawajah et al. Neuroepidemiology 2022;56:97-103). Read More


Effectiveness of COVID boosters in MS: an update


Two recent studies have reported that COVID boosters can increase the humoral response in MS patients during treatment with ocrelizumab or fingolimod. A number of studies have reported that these disease-modifying therapies (DMT) are associated with a blunted humoral response to COVID vaccination (Achiron et al. Ther Adv Neurol Disord 2021;14:17562864211012835. Gallo et al. Neurol Sci 2021;42:3523-3526). Read More